



**APCCC Detailed Program 2017 (subject to minor changes)**

**Areas of controversy**

1. Management of castration-sensitive prostate cancer
2. Management of castration-resistant prostate cancer (CRPC): M0 disease management and sequencing/combo treatment for metastatic CRPC
3. Use of novel imaging modalities
4. Molecular characterization: Tissue and blood based biomarkers in daily clinical practice
5. Germline mutations
6. Management of high risk and very high risk prostate cancer
7. Oligometastatic and oligo-progressive prostate cancer
8. Side effects of systemic treatment: Prevention and management
9. Palliative and supportive/preventive care and patient reported outcomes
10. Global access to prostate cancer drugs and treatment in countries with limited resources

**Thursday 9<sup>th</sup> March 2017**

<b>Time</b>	<b>Session</b>	
<b>09:00</b>	<b>Welcome Address:</b> Silke Gillessen and Aurelius Omlin on behalf of APCCC	
<b>9:15 -10:30 Session 1</b>	<b>Castration-sensitive prostate cancer: Part 1</b>	<b>Chairs: Chris Sweeney and Mack Roach</b>
	Definition: Castration-sensitive prostate cancer	Howard Scher
	When and how to use salvage radiation therapy in biochemical recurrence?	Alberto Bossi
	When and what hormonal therapy to use for men with castration-sensitive prostate cancer and isolated biochemical recurrence (M0) after radical treatment?	Martin Gleave
	Systemic treatment for men with high-risk and very high risk localised prostate cancer treated with curative intent	Nick James
<b>Coffee Break</b>		
<b>11:00 – 12:30 Session 2</b>	<b>Castration-sensitive prostate cancer: Part 2</b>	<b>Chairs: Karim Fizazi and Pirkko Kellokumpu-Lehtinen and Matt Sydes</b>
	Review the status of the ongoing and unreported clinical trials in M1 castration-sensitive space	Celestia Higano
	Should we be lumpers or slicers?	Susan Halabi
	Point/counterpoint: Chemo-hormonal therapy should be used for all men with castration-sensitive M1 disease fit for chemotherapy <ul style="list-style-type: none"> <li>• Pro</li> <li>• Contra</li> <li>• Arbiter</li> </ul>	Pro: Chris Parker Contra: Ian Tannock Arbiter: William Oh
	Is there a role for treating the primary in patients with metastatic disease	Axel Heidenreich
	Your patient received ADT plus docetaxel for M1 castration-sensitive disease - now what?	Chris Sweeney
<b>12:30 – 13:30 LUNCH</b>		
<b>13:30 – 15:00 Session 3</b>	<b>CRPC M0 and M1: Sequencing and Combination Therapy</b>	<b>Chairs: Eleni Efsthathiou and Eric Small</b>
	Castration-resistant prostate cancer – where are the questions	Eleni Efsthathiou



## ADVANCED PROSTATE CANCER CONSENSUS CONFERENCES

St. Gallen / Switzerland 9 – 11 March 2017

M0 CRPC: Does it still exist and if yes, to treat or not to treat?	Brett Carver
What is the optimal time to change treatment in men with mCRPC?	Karim Fizazi
Point/counterpoint: AR-V7 – Ready for use in daily clinical decision making? <ul style="list-style-type: none"> <li>○ Pro</li> <li>○ Contra</li> <li>○ Arbiter</li> </ul>	Pro: Phil Kantoff Contra: Tom Beer Arbiter: Chris Evans
Take home message	Eric Small
<b>COFFEE BREAK</b>	
<b>15:30 – 16:30</b> <b>Session 4</b>	<b>Molecular characterization Part 1</b> <b>Chairs: Ros Eeles and Howard Soule</b>
Next-generation or targeted sequencing of germline and somatic DNA in men with CRPC	Colin Pritchard
Patients with familial prostate cancer – practical implications and recommendations	Ros Eeles
<b>COFFEE BREAK</b>	
<b>17:00 – 18:45</b> <b>Session 5</b>	<b>Molecular characterization Part 2:</b> <b>Chairs: Mark Rubin, Johann de Bono, Gert Attard</b>
Aggressive variants of prostate cancer: When to look for it and how to treat it	Eric Small
Tumour biopsy in men with metastatic prostate cancer: What the pathologist should report	Mark Rubin
Taking action on molecular sub-types	Johann de Bono
Plasma based biomarkers in APC	Gert Attard
Circulating tumour cells – Ready for prime time?	Howard Scher

<b>Friday 10<sup>th</sup> March 2017</b>		
<b>Time</b>	<b>Session</b>	<b>Chair &amp; Speakers</b>
<b>Extra session</b> <b>08:00 – 08:20</b>	<b>Outcomes Research – Ironman project</b>	<b>Chair: Phil Kantoff</b>
	International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN)	Lorelei Mucci
<b>08:30 – 10:00</b> <b>Session 6</b>	<b>MOVEMBER SESSION: Global view on APC and access to novel drugs</b>	<b>Chairs: Ian Tannock and Gedske Daugaard and Raja Khauli</b>
	Availability of drugs (including pain medication): a major problem for the Global Fight against Cancer	Franco Cavalli
	Epidemiology and Treatment of APC in India	Vedang Murthy
	Epidemiology and Treatment of APC in Asian countries	Byung Ha Chung
	Epidemiology and Treatment of APC in South America	Fernando Maluf
	Pharmacokinetics and tolerance of prostate cancer drugs in Japan and other Asian countries	Hiroyoshi Suzuki
	Best use of “old and cheap” drugs	Ian Tannock
	Chair’s summary, panel discussion and questions	
<b>COFFEE BREAK</b>		



## ADVANCED PROSTATE CANCER CONSENSUS CONFERENCES

St. Gallen / Switzerland 9 – 11 March 2017

<b>10:30 – 12:00 Session 7</b>	<b>Localised prostate cancer</b>	<b>Chairs: Neal Shore and Avi Sella and Axel Heidenreich</b>
New imaging modalities for men with high-risk and very high-risk prostate cancer: What are the clinician's expectations		Mark Frydenberg
Local therapy in high-risk and very high-risk prostate cancer <ul style="list-style-type: none"> <li>• What is optimal surgery?</li> <li>• What is optimal radiation therapy?</li> </ul>		Nicolas Mottet Felix Feng
Quality control and standardisation of reporting for radical prostatectomy in locally advanced disease: <ul style="list-style-type: none"> <li>• What information the clinician needs from his pathologist</li> <li>• Pathologists reply</li> </ul>		Neal Shore Mark Rubin
Adjuvant treatment in men with unfavourable pathology after radical prostatectomy		Rob Bristow
<b>12:00 – 13:00 LUNCH</b>		
<b>13:00 – 14:30 Session 8</b>	<b>Supportive care and side effects of treatment</b>	<b>Chairs: Ian Davis and Matthew Smith and Daniel Castellano</b>
Prevention and treatment of side effects of ADT		Matthew Smith
Management of chronic pre-existing or treatment-emergent adverse events of the other systemic therapies		Michael Morris
Patient-reported outcome measures: How to use them in daily practise?		Sue Evans
Point/counterpoint: Bone targeted therapy with zoledronate or denosumab is required in men with metastatic CRPC responding to anticancer therapy <ul style="list-style-type: none"> <li>• Pro</li> <li>• Contra</li> <li>• Arbiter</li> </ul>		Pro: Fred Saad Contra: Noel Clarke Arbiter: Cora Sternberg
Involvement of the extended multidisciplinary management team		Ian Davis
<b>COFFEE BREAK</b>		
<b>15:00 – 16:30 Session 9</b>	<b>Oligometastatic and oligoprogressive prostate cancer (castration-sensitive and CRPC)</b>	<b>Chairs: Oliver Sartor and Piet Ost and Bertrand Tombal</b>
Overview and definition		Piet Ost
<u>Imaging</u> What are the clinician's needs in this situation? <ul style="list-style-type: none"> <li>➤ Answer of the nuclear medicine specialist</li> <li>➤ Answer of the radiologist</li> </ul>		Oliver Sartor Stefano Fanti Anwar Padhani
<u>Treatment of men with oligometastatic disease – castration-sensitive and castration-resistant: Debate</u> <ul style="list-style-type: none"> <li>• Multimodality treatment (local treatment all metastases +/- primary + systemic treatment)</li> <li>• Local treatment alone (surgical or radiation) of all lesions</li> <li>• No local treatment, systemic therapy alone (or watch and wait)</li> <li>• Arbiter: In the absence of good evidence, what to do in daily practice?</li> </ul>		Chuck Ryan  Mack Roach Nicholas Mottet Robert Bristow
Strategies for oligo-progressive CRPC		Bertrand Tombal
<b>COFFEE BREAK</b>		



## ADVANCED PROSTATE CANCER CONSENSUS CONFERENCES

St. Gallen / Switzerland 9 – 11 March 2017

<b>17:00 – 18:30</b> <b>Session 10</b>	<b>ESO OBSERVATORY: What will change for men with advanced prostate cancer in the next 24 months?</b>	<b>Chair: Riccardo Valdagni and Silke Gillessen</b>
<ul style="list-style-type: none"> <li>• Perspective on molecular characterization</li> <li>• Perspective on imaging (PET and MRI)</li> <li>• Perspective on endocrine and chemotherapy agents</li> <li>• Perspective on immunotherapy</li> <li>• Perspective on novel agents (including PARP)</li> <li>• Perspective on radiation therapy</li> <li>• Perspective on surgery</li> <li>• Patients perspective</li> </ul>		Himisha Beltran Gero Kramer Cora Sternberg Chuck Drake Chris Logothetis Thomas Wiegel Dos Reis Rodolfo Borges Ken Mastris

<b>Saturday 11<sup>th</sup> of March 2017</b>		
<b>Time</b>	<b>Special Session</b>	<b>Speakers</b>
<b>08:30 – 10:30</b>	<b>Consensus Panel – Discussion and votes on consensus questions – Part 1</b>	<b>ALL PANEL MEMBERS</b>
<b>COFFEE BREAK</b>		
<b>11:00 – 13:00</b>	<b>Consensus Panel – Discussion and votes on consensus questions – Part 2</b>	<b>ALL PANEL MEMBERS</b>
<b>Closing Remarks: S.Gillessen and A.Omlin</b>		